Mammary gland
HME1
Evercyte ́s human mammary epithelial cell line HME1 can be grown without limitations while maintaining expression of cell type specific markers and functions. Therefore, these cells are useful as standardized in vitro model to study processes such as breast cancer development, to test anti-tumor therapies or to perform toxicological tests.
Additionally, the cell line is the perfect starting material for genetic engineering to create important disease models.
General information
Cat#: CHT-044-0236
Morphology and expression of marker proteins
HME-1 cells are characterized by the typical epithelial cobblestone appearance and expression of mammary epithelial cell markers such as KRT8/18 and Mucin-1. Cell nuclei are counterstained with DAPI.
FAQs
In vitro propagation
MEGM Bullet kit (Lonza, Cat# CC-3150)
MEBM basal medium (Lonza, Cat# CC-3151)
Additional material & reagents
Phosphate buffered saline (PBS) (Sigma, Cat# D8537)
Trypsin inhibitor (Gibco, Cat# R007100)
0,05 % Trypsin-EDTA (Gibco, Cat#25300-054)
Passaging of cells
For detachment of the cells remove and discard the culture medium and wash the cells once with PBS (about 160 µl/cm²). Remove PBS completely.
Cryopreservation
Freezing medium
CryoStor® cell cryopreservation medium CS10 (Sigma Aldrich, Cat# C2874)
Additional material & reagents
Phosphate buffered saline (PBS) (Sigma, Cat# D8537)
0,05 % Trypsin-EDTA (Gibco, Cat# 25300-054)
Trypsin inhibitor (Gibco, Cat# R007100)
Freezing of cells
Detach the cells from the culture vessel by using Trypsin-EDTA and Trypsin-Inhibitor (Protocol passaging of HME1).
Thawing of cells
Original Evercyte cells are to be thawed in a T25 rouxflask
Product data sheet – certificate of analysis
Protocols
Data on Markers and Functions
Selected publications
Duan S, Nordmeier S, Byrnes AE, Buxton ILO. Extracellular Vesicle-Mediated Purinergic Signaling Contributes to Host Microenvironment Plasticity and Metastasis in Triple Negative Breast Cancer. Int J Mol Sci. 2021 Jan 9;22(2):597. https://pubmed.ncbi.nlm.nih.gov/33435297/
Licence Conditions
The business concept of Evercyte is to out-license telomerized cells to our customers. The license conditions depend on whether the contract partner is a for profit or a nonprofit organization and the intended use of the cells.
Nonprofit organizations
On time payment for unlimited use: EUR 1600
Profit organizations
Pharmaceutical – chemical- cosmetic industries
Contract research organizations (CRO)
Initial license fee for 3 months: EUR 2500Annual license fee R&D: royalty based
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
telomerized human lung fibroblasts
coming soon
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.